MX2021006559A - Analogos deuterados de acetil-leucina. - Google Patents
Analogos deuterados de acetil-leucina.Info
- Publication number
- MX2021006559A MX2021006559A MX2021006559A MX2021006559A MX2021006559A MX 2021006559 A MX2021006559 A MX 2021006559A MX 2021006559 A MX2021006559 A MX 2021006559A MX 2021006559 A MX2021006559 A MX 2021006559A MX 2021006559 A MX2021006559 A MX 2021006559A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- leucine
- acetyl
- treat
- present disclosure
- Prior art date
Links
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 title 1
- 229960000669 acetylleucine Drugs 0.000 title 1
- 208000015439 Lysosomal storage disease Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 230000003920 cognitive function Effects 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente descripción proporciona compuestos representados por la Fórmula I, y las sales y solvatos farmacéuticamente aceptables de los mismos, en donde R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, y R13 son como se definen en la especificación, y el enriquecimiento con deuterio de cualquiera de uno o más de R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, y R13 es aproximadamente 15% o más. La presente descripción también proporciona compuestos que tienen la Fórmula I para su uso para tratar o retrasar la progresión de un trastorno de almacenamiento lisosómico o una enfermedad neurodegenerativa en un sujeto, proporcionar neuroprotección en un sujeto que tiene un trastorno lisosómico, tratar o prevenir migraña y síntomas asociados con el mismo, en un sujeto, o mejorar la movilidad y/o función cognitiva en un sujeto. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776297P | 2018-12-06 | 2018-12-06 | |
| PCT/IB2019/060525 WO2020115715A1 (en) | 2018-12-06 | 2019-12-06 | Deuterated analogs of acetyl-leucine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021006559A true MX2021006559A (es) | 2021-08-16 |
Family
ID=68887086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006559A MX2021006559A (es) | 2018-12-06 | 2019-12-06 | Analogos deuterados de acetil-leucina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220024858A1 (es) |
| EP (1) | EP3886986A1 (es) |
| JP (1) | JP7471298B2 (es) |
| KR (1) | KR20210111757A (es) |
| CN (1) | CN113348018A (es) |
| AU (1) | AU2019391434A1 (es) |
| BR (1) | BR112021010923A2 (es) |
| CA (1) | CA3122223A1 (es) |
| IL (1) | IL283673A (es) |
| MA (1) | MA54289A (es) |
| MX (1) | MX2021006559A (es) |
| SG (1) | SG11202106009TA (es) |
| WO (1) | WO2020115715A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| WO2022264037A1 (en) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Branched-chain amino acid derivatives to treat disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026325A2 (en) * | 1994-03-25 | 1995-10-05 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
| AU2014214055A1 (en) | 2013-02-05 | 2015-07-16 | Teva Pharmaceuticals International Gmbh | Position-specific asymmetric deuterium enriched catecholamine derivatives and medicaments comprising said compounds |
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| SI3482754T1 (sl) * | 2016-08-11 | 2021-04-30 | Intrabio Ltd | Farmacevtski sestavki in uporabe usmerjene v motnje lizosomalnega shranjevanja |
| ME03454B (me) * | 2016-08-11 | 2020-01-20 | Intrabio Ltd | Terapeutski agensi za neurodegenerativne bolesti |
| GB201709459D0 (en) * | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| US10950670B2 (en) * | 2018-12-17 | 2021-03-16 | Wuhan China Star Optoelectronics Semiconductor Display Technology Co., Ltd. | Display panel |
| CN114040757A (zh) * | 2019-03-02 | 2022-02-11 | 内在生物技术有限公司 | 用于治疗疾病的亮氨酸、乙酰基亮氨酸和相关类似物 |
| EP3989962A1 (en) * | 2019-06-28 | 2022-05-04 | IntraBio Ltd | Combination therapy with acetyl-leucine and miglustat |
| WO2021144720A1 (en) * | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
| KR20230015433A (ko) * | 2020-05-22 | 2023-01-31 | 인트라바이오 리미티드 | 운동실조를 치료하기 위한 아세틸 류신과 4-아미노피리딘 또는 아세타졸아미드의 조합물 |
-
2019
- 2019-12-06 CA CA3122223A patent/CA3122223A1/en active Pending
- 2019-12-06 KR KR1020217019782A patent/KR20210111757A/ko not_active Application Discontinuation
- 2019-12-06 US US17/311,240 patent/US20220024858A1/en active Pending
- 2019-12-06 JP JP2021531964A patent/JP7471298B2/ja active Active
- 2019-12-06 EP EP19820881.1A patent/EP3886986A1/en active Pending
- 2019-12-06 AU AU2019391434A patent/AU2019391434A1/en active Pending
- 2019-12-06 MX MX2021006559A patent/MX2021006559A/es unknown
- 2019-12-06 SG SG11202106009TA patent/SG11202106009TA/en unknown
- 2019-12-06 WO PCT/IB2019/060525 patent/WO2020115715A1/en active Application Filing
- 2019-12-06 CN CN201980090399.8A patent/CN113348018A/zh active Pending
- 2019-12-06 MA MA054289A patent/MA54289A/fr unknown
- 2019-12-06 BR BR112021010923-4A patent/BR112021010923A2/pt unknown
-
2021
- 2021-06-03 IL IL283673A patent/IL283673A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019391434A1 (en) | 2021-07-08 |
| KR20210111757A (ko) | 2021-09-13 |
| MA54289A (fr) | 2021-10-06 |
| JP7471298B2 (ja) | 2024-04-19 |
| US20220024858A1 (en) | 2022-01-27 |
| WO2020115715A1 (en) | 2020-06-11 |
| SG11202106009TA (en) | 2021-07-29 |
| CN113348018A (zh) | 2021-09-03 |
| BR112021010923A2 (pt) | 2021-08-24 |
| JP2022514823A (ja) | 2022-02-16 |
| EP3886986A1 (en) | 2021-10-06 |
| IL283673A (en) | 2021-07-29 |
| CA3122223A1 (en) | 2020-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020014098A (es) | Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington. | |
| MX2018012379A (es) | Degradadores de proteinas de bromodominio y dominioextraterminal (bet). | |
| PE20191495A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2017010062A (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
| UA115881C2 (uk) | Алкоксипіразоли як активатори розчинної гуанілатциклази | |
| MX2019006296A (es) | Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. | |
| PH12015500776A1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
| MY161233A (en) | Bis (fluoroalkyl)-1, 4-benzodiazepinone compounds | |
| JOP20190239A1 (ar) | مركبات مثبطة لـ vmat2 وتركيبات منها | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| AR082201A1 (es) | Bencenosulfonamidas utiles como inhibidores del canal de sodio | |
| HRP20130614T1 (en) | Novel pyrazole-substituted arylamides | |
| MX2021006559A (es) | Analogos deuterados de acetil-leucina. | |
| PE20191082A1 (es) | Inhibidores de la tirosina quinasa de bruton | |
| MX2014006366A (es) | Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo. | |
| MY184433A (en) | 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders | |
| MX2022000376A (es) | Aminopirimidinas como inhibidores de alk. | |
| MD20170011A2 (ro) | Compuşi imidazopiridazinici | |
| MY170822A (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| ES2570766T3 (es) | Derivados del 1-bencil-3-hidroximetilindazol y su utilización en el tratamiento de enfermedades basadas en la expresión de MCP-1 y CX3CR1 | |
| AU2016275764A8 (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| MX2009009466A (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. | |
| PH12021550374A1 (en) | Small molecule menin inhibitors | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. |